Literature DB >> 19550416

AJG series: molecular biology for clinicians.

Yuri A Saito1, Nicholas J Talley.   

Abstract

Pharmacogenetics is an evolving field that provides the link between an individual's genetic code and drug metabolism and drug response. This field offers the great promise of individualized medication selection and optimized dosage to maximize treatment response and to minimize adverse side effects. As our understanding of the role of the effects of genetic variants on drug metabolism and body drug processing grows, so does our ability to educate and inform our patients about expected treatment response to the medications being prescribed to them. This brief review will provide an overview of genetics, pharmacogenetics, and current and future examples of genetic variants predicting drug response in gastrointestinal disease, and the limitations and the promise of this exciting and developing field.

Entities:  

Mesh:

Year:  2009        PMID: 19550416      PMCID: PMC2901906          DOI: 10.1038/ajg.2009.319

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  21 in total

1.  Rational dosing of azathioprine and 6-mercaptopurine.

Authors:  W J Sandborn
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Nomenclature for the description of human sequence variations.

Authors:  J T den Dunnen; S E Antonarakis
Journal:  Hum Genet       Date:  2001-07       Impact factor: 4.132

3.  Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.

Authors:  Takahisa Furuta; Naohito Shirai; Fumitoshi Watanabe; Satoru Honda; Ken Takeuchi; Takayuki Iida; Yoshihiko Sato; Masayoshi Kajimura; Hajime Futami; Shigekazu Takayanagi; Masami Yamada; Kyoichi Ohashi; Takashi Ishizaki; Hiroyuki Hanai
Journal:  Clin Pharmacol Ther       Date:  2002-10       Impact factor: 6.875

4.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.

Authors:  J F Colombel; N Ferrari; H Debuysere; P Marteau; J P Gendre; B Bonaz; J C Soulé; R Modigliani; Y Touze; P Catala; C Libersa; F Broly
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

5.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Authors:  Y Ando; H Saka; M Ando; T Sawa; K Muro; H Ueoka; A Yokoyama; S Saitoh; K Shimokata; Y Hasegawa
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

6.  A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer.

Authors:  J Stoehlmacher; V Ghaderi; S Iobal; S Groshen; D Tsao-Wei; D Park; H J Lenz
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

7.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

8.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

Authors:  L Iyer; S Das; L Janisch; M Wen; J Ramírez; T Karrison; G F Fleming; E E Vokes; R L Schilsky; M J Ratain
Journal:  Pharmacogenomics J       Date:  2002       Impact factor: 3.550

9.  Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.

Authors:  Wako Urano; Atsuo Taniguchi; Hisashi Yamanaka; Eiichi Tanaka; Hiroshi Nakajima; Yuko Matsuda; Hideto Akama; Yutaka Kitamura; Naoyuki Kamatani
Journal:  Pharmacogenetics       Date:  2002-04

10.  Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.

Authors:  Michael Camilleri; Elena Atanasova; Paula J Carlson; Umraan Ahmad; H Jae Kim; Blanca E Viramontes; Sanna McKinzie; Raul Urrutia
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

View more
  1 in total

1.  Polymorphisms of 5-HTT LPR and GNβ3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial.

Authors:  Yuri A Saito; G Richard Locke; Ann E Almazar; Ernest P Bouras; Colin W Howden; Brian E Lacy; John K DiBaise; Charlene M Prather; Bincy P Abraham; Hashem B El-Serag; Paul Moayyedi; Linda M Herrick; Lawrence A Szarka; Michael Camilleri; Frank A Hamilton; Cathy D Schleck; Katherine E Tilkes; Alan R Zinsmeister; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2017-03-14       Impact factor: 10.864

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.